TVARDI THERAPEUTICS INC (TVRD) Fundamental Analysis & Valuation

NASDAQ:TVRD • US1407553072

Current stock price

2.86 USD
-0.19 (-6.23%)
Last:

This TVRD fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. TVRD Profitability Analysis

1.1 Basic Checks

  • In the past year TVRD has reported negative net income.
  • TVRD had a negative operating cash flow in the past year.
  • TVRD had negative earnings in each of the past 5 years.
  • TVRD had a negative operating cash flow in each of the past 5 years.
TVRD Yearly Net Income VS EBIT VS OCF VS FCFTVRD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -20M -40M -60M -80M -100M

1.2 Ratios

  • The Return On Assets of TVRD (-35.74%) is comparable to the rest of the industry.
  • With a Return On Equity value of -50.04%, TVRD perfoms like the industry average, outperforming 52.60% of the companies in the same industry.
Industry RankSector Rank
ROA -35.74%
ROE -50.04%
ROIC N/A
ROA(3y)-114.14%
ROA(5y)-75.02%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
TVRD Yearly ROA, ROE, ROICTVRD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500 1K

1.3 Margins

  • TVRD's Gross Margin of 161.95% is amongst the best of the industry. TVRD outperforms 99.48% of its industry peers.
  • TVRD does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 161.95%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TVRD Yearly Profit, Operating, Gross MarginsTVRD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10K -20K -30K -40K -50K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. TVRD Health Analysis

2.1 Basic Checks

  • TVRD does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, TVRD has more shares outstanding
  • Compared to 5 years ago, TVRD has more shares outstanding
  • There is no outstanding debt for TVRD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
TVRD Yearly Shares OutstandingTVRD Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2M 4M 6M 8M
TVRD Yearly Total Debt VS Total AssetsTVRD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M 250M

2.2 Solvency

  • TVRD has an Altman-Z score of -3.14. This is a bad value and indicates that TVRD is not financially healthy and even has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -3.14, TVRD is in line with its industry, outperforming 40.10% of the companies in the same industry.
  • TVRD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -3.14
ROIC/WACCN/A
WACC8.46%
TVRD Yearly LT Debt VS Equity VS FCFTVRD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M -100M 200M

2.3 Liquidity

  • TVRD has a Current Ratio of 3.48. This indicates that TVRD is financially healthy and has no problem in meeting its short term obligations.
  • With a Current ratio value of 3.48, TVRD perfoms like the industry average, outperforming 56.77% of the companies in the same industry.
  • A Quick Ratio of 3.48 indicates that TVRD has no problem at all paying its short term obligations.
  • TVRD has a Quick ratio (3.48) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 3.48
Quick Ratio 3.48
TVRD Yearly Current Assets VS Current LiabilitesTVRD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. TVRD Growth Analysis

3.1 Past

EPS 1Y (TTM)N/A
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

  • Based on estimates for the next years, TVRD will show a quite strong growth in Earnings Per Share. The EPS will grow by 11.45% on average per year.
  • TVRD is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 87.40% yearly.
EPS Next Y55.29%
EPS Next 2Y22.59%
EPS Next 3Y13.5%
EPS Next 5Y11.45%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y87.4%

3.3 Evolution

TVRD Yearly Revenue VS EstimatesTVRD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2029 2030 2031 2032 2033 20M 40M 60M 80M 100M
TVRD Yearly EPS VS EstimatesTVRD Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 -20 -40 -60 -80

More info and screens

Find the best growth stocksShow best growing peers

0

4. TVRD Valuation Analysis

4.1 Price/Earnings Ratio

  • TVRD reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TVRD. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TVRD Price Earnings VS Forward Price EarningsTVRD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TVRD Per share dataTVRD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4

4.3 Compensation for Growth

  • TVRD's earnings are expected to grow with 13.50% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y22.59%
EPS Next 3Y13.5%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. TVRD Dividend Analysis

5.1 Amount

  • TVRD does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

TVRD Fundamentals: All Metrics, Ratios and Statistics

TVARDI THERAPEUTICS INC

NASDAQ:TVRD (4/9/2026, 1:28:08 PM)

2.86

-0.19 (-6.23%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-31
Earnings (Next)05-11
Inst Owners30.16%
Inst Owner Change0%
Ins Owners15.36%
Ins Owner Change0%
Market Cap26.83M
Revenue(TTM)N/A
Net Income(TTM)-13.95M
Analysts78.57
Price Target8.5 (197.2%)
Short Float %10.91%
Short Ratio13.29
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-14.65%
Min EPS beat(2)-71.45%
Max EPS beat(2)42.14%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 6.67
P/FCF N/A
P/OCF N/A
P/B 0.96
P/tB 0.97
EV/EBITDA N/A
EPS(TTM)-5.59
EYN/A
EPS(NY)-2.5
Fwd EYN/A
FCF(TTM)-2.33
FCFYN/A
OCF(TTM)-2.33
OCFYN/A
SpS0.43
BVpS2.97
TBVpS2.93
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -35.74%
ROE -50.04%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 161.95%
FCFM N/A
ROA(3y)-114.14%
ROA(5y)-75.02%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.1
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.48
Quick Ratio 3.48
Altman-Z -3.14
F-Score2
WACC8.46%
ROIC/WACCN/A
Cap/Depr(3y)678.01%
Cap/Depr(5y)443.34%
Cap/Sales(3y)8.69%
Cap/Sales(5y)5.3%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)N/A
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next Y55.29%
EPS Next 2Y22.59%
EPS Next 3Y13.5%
EPS Next 5Y11.45%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y87.4%
EBIT growth 1Y69.76%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year68.07%
EBIT Next 3Y12.96%
EBIT Next 5Y8.24%
FCF growth 1Y77.82%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y77.75%
OCF growth 3YN/A
OCF growth 5YN/A

TVARDI THERAPEUTICS INC / TVRD Fundamental Analysis FAQ

What is the fundamental rating for TVRD stock?

ChartMill assigns a fundamental rating of 3 / 10 to TVRD.


What is the valuation status of TVARDI THERAPEUTICS INC (TVRD) stock?

ChartMill assigns a valuation rating of 0 / 10 to TVARDI THERAPEUTICS INC (TVRD). This can be considered as Overvalued.


Can you provide the profitability details for TVARDI THERAPEUTICS INC?

TVARDI THERAPEUTICS INC (TVRD) has a profitability rating of 1 / 10.


How financially healthy is TVARDI THERAPEUTICS INC?

The financial health rating of TVARDI THERAPEUTICS INC (TVRD) is 6 / 10.


What is the earnings growth outlook for TVARDI THERAPEUTICS INC?

The Earnings per Share (EPS) of TVARDI THERAPEUTICS INC (TVRD) is expected to grow by 55.29% in the next year.